

ADC Portfolio Gaps in Big Pharma

 Portfolio gap

Company	Commercial	Late-Stage Development (Ph3+)	Early-Stage Development
 abbvie	Elahere (FRα)	Teliso-V (c-MET), Pivekimab (CD123 + IGN)	ABBV-319 (C19 / Steroid ADC), ABBV-400 (cMET + TOPO-1), ABBV-706 (SEZ6 + TOPO-1), IMGN151 (FRα + DM21 maytansinoid), ABBV-969 (PSMA STEAP1)
 AMGEN			LegoChem Collaboration (5 Assets), Synaffix Collaboration (5 Assets)
 AstraZeneca	Enhertu (HER2)	Dato-DXd (TROP2), AZD0901 (CLDN18.2)	AZD9592 (EGFR + c-MET), AZD8205 (B7-H4), AZD5335 (FRα), AZD0305 (GPRC5D), AZD9829 (CD123 TOP1i)
 Bristol Myers Squibb			MORAb-202 (FRα), TPX-4589 (CLDN18.2), BL-B01D1 (EGFR + HER3), ORM-6151 (CD33 + GSPT1), Tubulis Collaboration (Undisclosed)
 Daiichi-Sankyo	Enhertu (HER2)	Dato-DXd (TROP2), HER3-DXd (HER3)	R-DXd (CDH6), I-DXd (B7-H3), DS-9606 (CLDN6), DS-3939 (MUC1)
 Lilly			ADC-1 (Nectin-4), AbbVie Collaboration, MBK-103 (FOLR1)
 GILEAD	Trodelvy (TROP2)		
 GSK		Blenrep (BCMA)	XMT-2056 (STING), GSK5733584 (B7-H4), GSK5764227 (B7-H3)
 J&J			JNJ-8177 (PSMA), JNJ-0683 (HER2), JNJ-0631 (CD70) LCB84 (TROP2), Mersana Collaboration
 MERCK		MK-2140 (ROR1), MK-2870 (TROP2), HER3-DXd (HER3)	R-DXd (CDH6), I-DXd (B7-H3), SKB315 (CLDN18.2)
 NOVARTIS			
 Pfizer	Mylotarg (CD33), Adcetris (CD30), Padcev (Nectin-4), Besponsa (CD22), Tivdak (TF)	SGN-B6A (ITGB6), DV (HER2)	SGN-B7H4V (B7-H4), SGN-PDL1V (PD-L1), SGN-35T(CD30), SGN-CEACAM5C (CEACAM5C), HBM9033 (MSLN)
 Roche	Polivy (CD79), Kadcyra (HER2)		YL-211 (c-MET)